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Abstract
OBJECTIVE: To determine the effects of decoction
derived from the leaves of Nicotiana tabacum (L.)
as a mouthwash on minor recurrent aphthous.
METHODS: A randomized double-blinded place-
bo-controlled clinical trial was conducted on 60 pa-
tients with minor recurrent aphthous. Treatment
comprised of application of tobacco or placebo
mouthwash (10 mL 3 times a day) for 5 days. Clini-
cal evaluation included pain level using a visual an-
alog scale and ulcer size on days 1, 3, and 5 were
measured. Adverse effects after mouthwash appli-
cation were recorded, and the oral mucosa was ex-
amined by the investigator at each visit.
RESULTS: A total of 54 subjects with the mean age
(38 ± 10) years fulfilled the study. No minor and ma-
jor adverse effects were observed. In the treatment
group, ulcer pain score was decreased by 79.2%
and 93.8% and ulcer size was reduced by 69.1%
and 92.2% (days 3 and 5, respectively), which was
significantly greater than the control group (P <
0.01).
CONCLUSION: The decoction prepared with of Ni-
cotiana tabacum leaves, used as mouthwash are
well-tolerated and safe, and can be used for the
management of recurrent aphthous.
© 2016 JTCM. All rights reserved.
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INTRODUCTION
Recurrent aphthous ulcers (also termed canker sores)
are currently one of the most common inflammatory
ulcerative disorders of the oral mucosa.1,2 This condi-
tion is characterized by painful, recurrent and single or
multiple ulceration of the oral cavity that affect nearly
10%-20% of the general population.2,3 The ethiopatho-
genesis of aphthae is unclear but some factors such as
heredity, immune dysregulation, hematinic deficiency
(like iron, folic acid, vitamin B6 and B12), stress, local
trauma, infections and systemic diseases (Behcet's syn-
drome) have been proposed as causative factors.4,5 De-
spite the multi-factorial etiology of the disease, most of
the treatments for aphthae are designed to reduce pain
and inflammation. However, in order to eliminate or
reduce the symptoms, we need to search safer and
more effective agents with multi-bioactivities.6 Nowa-
days, there is an increasing tendency to use herbal med-
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icines for the treatment of aphthae and several herb's
extracts have been evaluated for this propose.7-11
The genus Nicotiana (L.) (Family: Solanaceae) compris-
es about 100 species and natively distributed in tropi-
cal America.12-16 Three species of this genus, Nicotiana
gluaca, Nicotiana rustica and Nicotiana tabacum are
cultivated in Iran with the common Persian name of
"Tanbakoo".17 Nicotiana tabacum, of the most com-
mercially valued agricultural herbs in the world, has
half hardy annual subshrubs with rose-coloured flowers
and elliptic-ovate leaves.12-14 In folk medicine, the leaves
of tobacco have been used in the treatment of back-
ache, toothache, lumbago, gastrosis, ulcers and
wounds.12-14 As a medicinal plant, leaves have been used
due to their sedative, narcotic, emetic and antispasmod-
ic activities and applied for the rheumatic swelling and
skin disorders.12,14,15 According to the literature, differ-
ent biological compounds, such as, isoflavones,13 phe-
nolic acids,15 sesquiterpenes,16,18 diterpenoids,19,20 and al-
kaloids were isolated from tobacco but alkaloid constit-
uents, chiefly nicotine, are the most important part of
these components due to their main pharmacological
and biological activities.21,22 Moreover, several reports re-
vealed that smoking has potential inhibitory effects on
the occurrence of aphthous ulcers.3,23-25 In the light of
above findings, it is reasonable to assess the anti-aph-
thous activity of tobacco leaves extract against aph-
thous ulcers. In the present study, anti-aphthous activi-
ty of the leaf decoction from Nicotiana tabacum as a
mouthwash was evaluated on patients with recurrent
aphthous ulcers.
MATERIALS ANDMETHODS
Preparation of decoction and formulation (Sample
preparation)
Dried leaves of Nicotiana tabacum were purchased
from local bazaar market, Kermanshah, Iran.
500 grams of Nicotiana tabacum leaves was ground
and decocted with 10-folded mass of water (5000 mL)
for 30 min, filtered, and then let the decoction be
cooled down to room temperature. For preparation of
a mouthwash, 3000 mL of filtrated decoction was
mixed with 3 grams of a mixture of methylparaben and
propylparaben (9∶1) as preservatives. In addition, pla-
cebo was prepared in similar container including dis-
tilled water with approved color additives which
looked the same as the tobacco mouthwash. The place-
bo mouthwash also had similar label as the tobacco
mouthwash preparation.
Subjects and study design
In this randomized double-blinded placebo-controlled
clinical study, 60 patients were assigned into group of
placebo (n = 30) and group of tobacco treatment (n =
30). Patients were seen at the Infectious Diseases Clin-
ic, Kermanshah University of Medical Sciences, Ker-
manshah. Randomization of equal number of subjects
to placebo or treated group was achieved using a sim-
ple random allocation strategy, using block randomiza-
tion method according to CONSORT Statement
(2010). The participants were instructed to apply 10
mL of mouthwash, 3 times a day for 5 days. Likewise,
the patients in placebo group were instructed to use
the placebo mouthwash the same as treatment group
(10 mL of mouthwash, 3 times a day for 5 days). The
baseline factors were taken and recorded on the day of
the first visit. All of the subjects were free to withdraw
at any time during the course of study. All participants
signed a written informed consent before recruiting in
the study. The Ethics Committee of Kermanshah Uni-
versity of Medical Sciences approved this clinical study
(approval number: KUMS. REC.1394.14).
To exclude potentially confounding systemic diseases,
all patients underwent careful examination by derma-
tologists, gastroenterologists, and ophthalmologists be-
fore enrollment. The clinical diagnosis was made by in-
fectious medicine specialists based on clinical appear-
ance, location, and patient history. All patients were se-
lected according to specific inclusion and exclusion cri-
teria. The inclusion criteria were as follows: (a) men
and women (males and females) aged 15-65 years old
who can follow the doctor's advice; (b) Willingness to
participate and sign the informed agreement forms; (c)
patients with 1 to 5 aphthous ulcers (less than 48
hours' duration); (d) an anticipation that their ulcers
normally take 5 or more days to resolve without treat-
ment; (e) ulcers must be in positions simply accessible
for evaluation and treatment, such as the labial muco-
sa, buccal mucosa, or the tongue; and (f ) patients with
normal sense of pain. Exclusion criteria were the fol-
lowing: (a) a known history of severe drug hypersensi-
tivities, particularly allergies to tobacco or nicotin; (b)
pregnancy or lactation; (c) ulcers as a manifestation of
a systemic disease process, including Behçet disease, se-
rious anemia Crohn's disease, ulcerative colitis, or ac-
quired immune deficiency syndrome; (d) simultaneous
clinical conditions which represent a health risk to the
subjects, such as severe heart, liver, or kidney disorder;
(e) treatment with systemic non-steroidal anti-inflam-
matory drugs, systemic steroids or other immunomod-
ulatory agents, oral antihistamines, or systemic antibi-
otics within 2 weeks study entry; (f ) treatment of the
ulcer with any medication within 72 h before study en-
try; and (g) attendance of any clinical studies within 2
months before trial entry.
Measurement
In all studies, the size and number of ulcers were calcu-
lated by the investigator, and the pain was assessed by
the subjects before the first mouthwash application
and at each subsequent evaluation. For patients who
had more than 1 ulcer, only the ulcer that occurred
lately and was easy for evaluation was selected. Periodic
telephone interviews were performed to supervise the
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administration on schedule. Adverse effects after
mouthwash application were recorded, and the oral
mucosa was examined by the investigator at each visit.
Evaluation of pain was performed using a visual analog
scale (VAS) containing a 10-cm horizontal line be-
tween the poles of "no pain" and "unbearable pain".
Patients were instructed to mark the line with a vertical
line at the point that best characterized the present
pain level of the aphthous. In order to calculate the size
of the ulcers, the investigators measured the distance
between 2 opposite outside edges of the white border
in term of millimeter. Two measurements approximate-
ly 90 degrees from each other were determined; the
largest distance was used as one of the measurements.
The 2 measurements were then multiplied to represent
the cross-sectional areas of the aphthous.
In order to compare the efficacy of treatment statistical-
ly at different time points the data were calculated by
means of the following formula [(visit 1-visit 3 or 5) /
visit 1] × 100% (visit a referring to the therapeutic indi-
ces measured at day a), as described previously.5
Statistical analysis
Comparison of baseline characteristics between place-
bo-control and treatment group were performed by
t-test and c2 test. Differences between tobacco treat-
ment group and placebo group were evaluated in each
visit using Chi-square and the Mann-Whitney U test.
Statistical significance was set at P < 0.05. All data
were analyzed with SPSS software (Released 2009.
SPSS Statistics for Windows, Version 18.0. SPSS Inc.
Chicago, IL, USA).
RESULTS
A total of 60 subjects were recruited for this study. On-
ly 3 subjects in treatment group and 3 patients in place-
bo-control group dropped out because of conflicting
schedule and not following the treatment. Thus, 27
subjects in treatment group and 27 subjects in place-
bo-control group fulfilled the study.
Baseline characteristics
There were no statistically significant differences in
baseline characteristics between the 2 groups. Hence,
the groups were homogenous with respect to age, sex,
as well as known allergies. Likewise, the baseline levels
of ulcer size, numbers, as well as pain score were not
significantly difference between treatment and control
groups (P > 0.05). Age of the patients ranged from 21
to 58 years with the mean age (38 ± 10) years. Among
the patients, 48.2% were women and 51.8% were men
(Table 1).
Improving pain
As shown in Table 2, the mean pain score of the treat-
ment group and the placebo-control group were not
significantly different (P > 0.05) at the baseline (day 1,
before administration of the treatment). The ulcer pain
score in all of the study days after treatment with tobac-
co mouthwash was significantly lower than that of pla-
cebo-control values (P < 0.01). At day 3, ulcer pain
score in the tobacco group was decreased by 79.2% ,
which was significantly higher than that of the control
group (22.3% , P < 0.01). Likewise, at the day 5 of
study, ulcer pain score in the treatment group (tobacco
mouthwash) was lessened by 93.8%, which was statisti-
cally different in comparison with the level of placebo
group (44.6%, P < 0.01).
Ulcer measurement
Table 3 shows the ulcer size in term of millimeter at
study entry day and after treatment with tobacco
mouthwash and placebo. At day 1, mean ulcer size of
the treatment and control groups were not significantly
different (P > 0.05). The ulcer size in all of the days af-
ter treatment was significantly different in comparison
with placebo-control group (P < 0.01). At the day 3 of
study, the ulcer size in the treatment group (tobacco
mouthwash) was decreased by 69.1%, which was high-
er than the 22.9% observed in the placebo group (P <
0.01). On day 5 of the study, the ulcer size decreased
by 92.2% which was significantly greater than the level
of placebo group (50.1%, P < 0.01).
Group
Tobacco
Placebo
No. of patients
(n)
27
27
Gender (n)
Female
14
12
Male
13
15
No. of ulcers
3.1±0.7
3.2±0.8
Year of age
Range
20-54
21-58
xˉ ± s
37.2±10.1
38.1±10.3
Notes: patients with aphthous in tobacco group were treated with mouthwash of Nicotiana tabacum leaves decoction, and patients with
aphthous in placebo group were treated with blank mouthwash which looked the same as the tobacco mouthwash.
Table 1 Clinical characteristics of patients with aphthous ( xˉ ± s)
Table 2 Ulcer pain score of treatment and placebo-control groups at different time points ( xˉ ± s)
Group
Tobacco
Placebo
Day 1
4.1±2.3
4.0±2.2
Day 2
2.4±2.2a
3.6±1.8
Day 3
1.1±1.4a
3.1±1.8
Day 4
0.7±1.0a
2.7±1.5
Day 5
0.4±0.6a
2.1±1.3
Notes: patients with aphthous in tobacco group were treated with mouthwash of Nicotiana tabacum leaves decoction, and patients with
aphthous in placebo group were treated with blank mouthwash which looked the same as the tobacco mouthwash. Compared with the pla-
cebo-control group, aP < 0.01.
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Safety evaluation
No clinical adverse effect including hypersensitivity,
taste sense malfunction, and infection were reported.
All subjects tolerated the mouthwash well with a good
score.
DISCUSSION
Recurrent aphthous ulcers is an episodic and self-limit-
ed disease and period of the ulcers is usually 7-10 days
but it causes remarkable pain, suffering ulceration and
inconvenience for patients as well as adversely affecting
the quality of life.2 For these reasons, reducing the pain,
inflammation and ulcer size, decrease in the frequency
of recurrence and also healing promotion are the main
aims of therapy.2-5
Natural medicine is considered as a safe and efficacious
complementary and alternative therapy for various dis-
eases.26,27 In traditional and folklore medicine of differ-
ent nations all over the world including Persian medi-
cine several plant-derived natural remedies have been
used for the management of dermal as well as mucosal
ulcers for thousands of years.28,29
Results obtained from current study indicated that de-
coction of leaves of Nicotiana tabacum was adminis-
trated as a mouthwash and showed remarkable effect
to treat aphthous ulcers. This is in line with the obser-
vations by Subramanyam,3 Koybasi et al,25 Grady et al 24
and Shapiro et al 23 and supports their hypothesis that
cigarette smoking has a protective activity on occur-
rence of aphthous ulcers.3,23-25 Combustible products of
smoking are known to stimulate an increased keratini-
zation of the oral mucosa and therefore resist forma-
tion of aphthous ulcers and reduce trauma or bacterial
penetration of the mucous membrane in smokers
when compared to non-smokers.3,24 This property may
be attributed to the presence of the main alkaloid of
Nicotiana tabacum, Nicotine, which showed remark-
able protective effect in aphthous ulcers and Behcet
syndrome by using oral nicotine replacement therapy.30
Nicotine and its metabolites exhibited immunosuppres-
sive activity and lead to reduction in inflammatory con-
dition by different known mechanisms including anti-
body-forming cell response, suppression of neutrophil
mediated inflammatory action, inhibition of endotheli-
al cell release of interleukin (IL)-8, inhibition of IL-1β,
IL-2, IL-10, tumor necrosis factor (TNF)-α and inter-
feron (IFN)-γ release, reduction in circulation levels of
immune globulins, impairment of antigen-mediated
signaling in T-cells and inducing T-cell allergy as well
as attenuation of IFN signaling.3,30 Moreover, previous
investigations revealed that different extracts of Nicotia-
na tabacum leaves have a significant range of inhibito-
ry effect on different bacterial species that result in im-
provement of disease process.27,31
In conclusion, the present clinical study exhibits that
the mouthwash of decoction of Nicotiana tabacum
leaves possess a remarkable potential to reduce pain
and promote ulcer healing with minimal safety con-
cerns. Thus, current clinical practice confirmed the effi-
cacy of Nicotiana tabacum leaves mouthwash as a
well-tolerated and safe adjunctive therapy for the man-
agement of recurrent aphthous. More well-designed
randomized controlled clinical trial is suggested in or-
der to recognize the mechanisms of action and thera-
peutic aspects of this natural mouthwash.
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